Abiraterone Acetate plus prednisone was undergoing Phase 3 clinical trials on patients with metastatic advanced prostate cancer (castration-resistant prostate cancer) when an Independent Data Monitoring Committee recommended unblinding the study – this means the patients who were not receiving the Abiraterone Acetate should be offered it, Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc. announced.
The Committee determined that treatment with Abiraterone Acetate plus prednisone “demonstrated a statistically significant improvement in overall survival and an acceptable safety profile.”
The participating patients, 1,195 of them, had metatastic advanced prostate cancer, also known as castration-resistant prostate cancer, their disease had progressed after treatment with one or two chemotherapy regimes, at least one of which contain docetaxel.
They had been randomly selected to receive abiraterone acetate plus prednisone or placebo plus prednisone.
Ortho Biotech say they are initiating a program that will provide early access to abiraterone acetate to patients who meet certain medical criteria. When they are ready to enroll patients, details will be listed on www.clinicaltrials.gov. The program is expected to open in October in the USA and in other countries shortly afterwards.
In a press release, Ortho Biotech Oncology Research & Development writes:
Abiraterone acetate is an investigational drug; its safety and efficacy have not yet been established. The company is evaluating the filing strategy for abiraterone acetate, based on the IDMC’s recommendation to unblind this study.
Prostate cancer is a disease which only affects men. Cancer begins to grow in the prostate – a gland in the male reproductive system. The prostate is an exocrine gland of the male reproductive system, and exists directly under the bladder, in front of the rectum. An exocrine gland is one whose secretions end up outside the body e.g. prostate gland and sweat glands. It is approximately the size of a walnut.
The urethra – a tube that goes from the bladder to the end of the penis and carries urine and semen out of the body – goes through the prostate.
There are thousands of tiny glands in the prostate – they all produce a fluid that forms part of the semen. This fluid also protects and nourishes the sperm. When a male has an orgasm the seminal-vesicles secrete a milky liquid in which the semen travels. The liquid is produced in the prostate gland, while the sperm is kept and produced in the testicles. When a male climaxes (has an orgasm) contractions force the prostate to secrete this fluid into the urethra and leave the body through the penis.
As the urethra goes through the prostate: the prostate gland is also involved in urine control (continence) with the use of prostate muscle fibers. These muscle fibers in the prostate contract and release, controlling the flow of urine flowing through the urethra.
The epithelial cells in the prostate gland produce a protein called PSA (prostate-specific antigen). The PSA helps keep the semen in its liquid state. Some of the PSA escapes into the bloodstream. We can measure a man’s PSA levels by checking his blood. If a man’s levels of PSA are high, it might be an indication of either prostate cancer or some kind of prostate condition.
It is a myth to think that a high blood-PSA level is harmful to you – it is not. High blood PSA levels are however an indication that something may be wrong in the prostate.
Male hormones affect the growth of the prostate, and also how much PSA the prostate produces. Medications aimed at altering male hormone levels may affect PSA blood levels. If male hormones are low during a male’s growth and during his adulthood, his prostate gland will not grow to full size.
In some older men the prostate may continue to grow, especially the part that is around the urethra. This can make it more difficult for the man to pass urine as the growing prostate gland may be causing the urethra to collapse. When the prostate gland becomes too big in this way, the condition is called Benign Prostatic Hyperplasia (BPH). BPH is not cancer, but must be treated.
In the vast majority of cases, the prostate cancer starts in the gland cells – this is called adenocarcinoma.
Prostate cancer is mostly a very slow progressing disease. In fact, many men die of old age, without ever knowing they had prostate cancer – it is only when an autopsy is done that doctors know it was there. Several studies have indicated that perhaps about 80% of all men in their eighties had prostate cancer when they died, but nobody knew, not even the doctor.
Experts say that prostate cancer starts with tiny alterations in the shape and size of the prostate gland cells – Prostatic intraepithelial neoplasia (PIN). Doctors say that nearly 50% of all 50-year-old men have PIN. The cells are still in place – they do not seem to have moved elsewhere – but the changes can be seen under a microscope. Cancer cells would have moved into other parts of the prostate. Doctors describe these prostate gland cell changes as low-grade or high-grade; high grade is abnormal while low-grade is more-or-less normal.
Any patient who was found to have high-grade PIN after a prostate biopsy is at a significantly greater risk of having cancer cells in his prostate. Because of this, doctors will monitor him carefully and possibly carry out another biopsy later on.
Click here to read about prostate cancer in more detail.
Written by Christian Nordqvist